Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 2/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9108244 | 0.86 | KDM1A (0.34) | ALOX15 | |
| SCHEMBL30350420 | 0.86 | KDM1A (0.34) | ALOX15 | |
| SCHEMBL21979280 | 0.82 | CA9 (0.36) | IDO1CA12CA1CA9ALOX15 | |
| SCHEMBL13550170 | 0.82 | RAPGEF4 (0.32) | — | |
| SCHEMBL15287359 | 0.82 | EPAS1 (0.33) | ALOX15EPAS1 | |
| Boric Acid SCHEMBL2464707 | 0.78 | GAA (0.32) | IDO1CA1 | |
| SCHEMBL30038863 | 0.78 | EPAS1 (0.41) | IDO1ALOX15EPAS1 | |
| SCHEMBL24868763 | 0.77 | PGK1 (0.31) | — | |
| SCHEMBL21979047 | 0.77 | NPC1 (0.41) | — | |
| SCHEMBL792557 | 0.77 | TRPV4 (0.35) | EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103664511-B | Preparation method of 5-bromo-1,3-dichloro-2-fluorobenzene | SHANGYU LINJIANG CHEMICAL CO LTD | 2015-07-08 | — | — | CN | claimed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4541422-A2 | QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS | Gilead Sciences, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119462635-A | Quinoline derivatives as alpha 4 beta 7 integrin inhibitors | 吉利德科学公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3873884-B1 | 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDIN-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GILEAD SCIENCES INC (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-112969687-B | Quinoline derivatives as a4 b 7 integrin inhibitors | 吉利德科学公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112996786-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-08-20 | — | — | CN | disclosed |
| US-12053462-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| WO-2019214399-A1 | BENZO- SEVEN-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | 罗欣药业(上海)有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-28 | — | — | US | disclosed |
| EP-3288936-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176449-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
| CN-103664511-B | Preparation method of 5-bromo-1,3-dichloro-2-fluorobenzene | SHANGYU LINJIANG CHEMICAL CO LTD | 2015-07-08 | — | — | CN | disclosed |
| US-6242451-B1 | Fungicidal trihalophenyl-triazolopyrimidines | BASF AKTIENGESELLSCHAFT | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12053462-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | IDO1 864/4885CYP1A2 185/4885CYP2A6 834/4885 |
| US-10611730-B2 | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | GRIN1, GABRE, GRIN3A | IDO1 2555/4885CYP1A2 2120/4885CYP2A6 2061/4885 |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | IDO1 4608/4885CYP1A2 4048/4885CYP2A6 3555/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | IDO1 864/4885CYP1A2 185/4885CYP2A6 834/4885 |
| US-20190092735-A1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GABRE, GRIN3A | IDO1 2555/4885CYP1A2 2120/4885CYP2A6 2061/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | IDO1 4856/4885CYP1A2 4676/4885CYP2A6 3972/4885 |
| US-20250032473-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | IDO1 864/4885CYP1A2 185/4885CYP2A6 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.